Skip to content

Angiotensin II for Septic Shock Treatment

Angiotensin II for Septic Shock Treatment: Effects On Macro- and Microcirculation A Randomized, Controlled Pilot Trial (ANGSTROM Trial)

Status
Suspended
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03302650
Enrollment
20
Registered
2017-10-05
Start date
2019-04-01
Completion date
2019-08-15
Last updated
2019-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Brief summary

This study aims to investigate the effect of angiotensin II on microcirculation and peripheral perfusion in patients with septic shock.

Detailed description

Shock is a syndrome characterized by acute circulatory failure resulting in impaired peripheral tissue perfusion. Distributive shock is the most common type of shock and is usually caused by severe sepsis. Distributive shock is characterized by profound vasodilatation leading to decreased arterial blood pressure and impaired organ perfusion despite high cardiac output. The use of vasopressors is an essential management line for distributive sock. Two groups of vasopressors are usually used for management of shock: catecholamines and vasopressin-like peptides. There is a continuous need for other vasopressors because: 1- Available vasopressors have narrow therapeutic window. 2- Patients with severe hypotension refractory to the currently available classes usually die. A third system is usually engaged in the physiology of shock which is Renin-Angiotensin-aldosterone system. Angiotensin II is a natural hormone which is a potent vasopressor; moreover, angiotensin II stimulates the production of both antidiuretic hormone and adrenocorticotropin hormone. In a pilot study, angiotensin II was reported as an effective rescue vasopressor in septic shock patients on multiple vasopressors. Angiotensin II improved mean arterial pressure and helped in reduction of the doses of catecholamines. In a recent large randomized controlled trial, angiotensin II improved blood pressure in catecholamine-resistant distributive shock patients. Microcirculation is the primary site of oxygen and nutrient exchange. Maintenance of microcirculatory perfusion is a prerequisite for preservation of organ function. Multiple organ failure is common in patients with distributive shock despite maintenance of parameters of global perfusion due to disrupted microcirculatory perfusion. Furthermore, restoration of microcirculatory perfusion was correlated with improvement in survival. This study aims to investigate the effect of angiotensin II on peripheral microcirculation in patients with septic shock.

Interventions

DRUGAngiotensin II

Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.

DRUGNormal saline

Patients will receive normal saline.

DRUGNorepinephrine

patients will receive norepinephrine infusion adjusted according to blood pressure

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Septic shock patients. * Aged above 18 years. * With cardiac index \> 2.4 L/min/BSA 1.73 m2. * On high dose vasopressors (defined as norepinephrine infusion above 0.1 mcg/Kg/min)

Exclusion criteria

* Acute coronary syndrome. * Impaired cardiac contractility * Bronchospasm. * Major burns * Liver failure. * Active bleeding.

Design outcomes

Primary

MeasureTime frameDescription
Mean flow index6 HoursMean flow index measured by Side stream dark field imaging optical probe (Microscan; MicroVision Medical, Amsterdam, Netherlands). Briefly, after gentle cleansing of the tongue by isotonic-saline-drenched gauze, avoiding pressure artifacts, 5 steady images of at least 20 seconds each will be obtained and stored under a random number. Offline blind analysis of each video will be done using a dedicated software (Automated Vascular Analysis 3.0; Academic Medical Center, University of Amsterdam, The Netherlands). The microvascular flow index (MFI) will be used to quantify microvascular blood flow. In this score, flow is characterized as absent (0), intermittent (1), sluggish (2), or normal (3), for each patient the values from 5 videos will be averaged. Since our investigation will be focused on small vessels, calculations will be separately performed for vessels with a diameter less than 20 ųm.

Secondary

MeasureTime frameDescription
Perfused vessel density6 HoursPerfused vessel density measured by Side stream dark field imaging optical probe (Microscan; MicroVision Medical, Amsterdam, Netherlands). Briefly, after gentle cleansing of the tongue by isotonic-saline-drenched gauze, avoiding pressure artifacts, 5 steady images of at least 20 seconds each will be obtained and stored under a random number. Offline blind analysis of each video will be done using a dedicated software (Automated Vascular Analysis 3.0; Academic Medical Center, University of Amsterdam, The Netherlands)
systolic blood pressure6 hourssystolic blood pressure measured in mmHg
Diastolic blood pressure6 hoursdiastolic blood pressure measured in mmHg
Heart rate6 hoursheart rate in beats per minute
Serum lactate6 hoursSerum lactate measured in milligrams per deciliter
Urine output6 hoursquantity of urine in milliliters
Serum Creatinine24 hoursserum creatinine measured in milligrams per deciliter
Proportion of perfused vessels6 HoursProportion of perfused vessels measured by Side stream dark field imaging optical probe (Microscan; MicroVision Medical, Amsterdam, Netherlands). Briefly, after gentle cleansing of the tongue by isotonic-saline-drenched gauze, avoiding pressure artifacts, 5 steady images of at least 20 seconds each will be obtained and stored under a random number. Offline blind analysis of each video will be done using a dedicated software (Automated Vascular Analysis 3.0; Academic Medical Center, University of Amsterdam, The Netherlands)
Serum potassium24 hoursSerum potassium measured in milligrams per deciliter
Cardiac output6 hoursquantity of blood pumper by the heart measured by electrical cardiometry in liters per minute
systemic vascular resistance6 hourssystemic vascular resistance measured by electrical cardiometry
Norepinephrine requirements6 hourstotal requirement of norepinephrine needed to maintain mean arterial blood pressure above 65 mmHg
perfusion index6 hoursproportion of pulsatile to non-pulsatile portions in peripheral circulation
total fluid intake24 hoursamount of fluids received by the patient in milliliters
Serum Sodium24 hoursSerum sodium measured in milligrams per deciliter

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026